LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, our mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health.
Our portfolio companies are deploying AI for personalized cancer treatments, pioneering epigenetic reprogramming, saving lives with early ovarian cancer diagnosis and more.
Join the fund using the Get in Touch buttons below.
Join the fund using the Get in Touch buttons below.
ABOUT US
The LongeVC team and Advisory Board thoroughly vet all investments to guarantee impact, growth potential and success.
Our portfolio companies have:
Lean operational structure
Rapid scaling plan to reach seed stage
Publications
in peer-reviewed journals
Experienced and ambitious talent
Proof
of concept
OUR TEAM
Managing Partner
Garri Zmudze
Managing Partner
Ilya Suharenko
Managing Partner
Sergey Jakimov
Head of Advisory Board
Alex Zhavoronkov
First industrial validation and partnership commitments
We are curating an ecosystem of biotech and longevity-focused companies ready to change the world. When we invest in a company, we connect them with a network of experienced visionaries and opportunities ready to make progress.
OUR COMMUNITY
Artificial Intelligence for Drug Discovery and Aging Research.
Unlocking the power of life data without borders. Providing the industry with tools for prospective research and R&D acceleration.
Different breeds. Different needs. Every cat is unique. Get to know your cat better with a Cat DNA Test.
A SaaS solution integrating multiple deep biomarkers of aging dubbed 'deep aging clocks' to provide a universal multifactorial measure of human biological age.
Creating mRNA medicines specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue.
Developing the first accurate early stage non-invasive ovarian cancer diagnostic test that will improve clinical practice, help reduce patient mortality and deliver cost savings to payers.
Bringing together innovators and investors to commercialise the companies that will form the Longevity economy.
Creating a groundbreaking personalized oncology platform that uses tumor twins and AI-supported testing for more effective cancer treatment plans.
Applying genetic engineering and aging models for rejuvenation and enhancement therapeutics.
Developing cutting-edge ketamine treatments for difficult-to-treat mental health conditions.
Delivering faster and more accurate diagnostics for pathogen detection in infants.
ACCELERATION
Our two-track acceleration program supports founders and pre-seed startups in their earliest stages by providing access to capital, expert advising and curated relationship-building with key industry stakeholders.
We believe that successful teams can be created from the ground up as industry trends emerge around them.
To get the most out of this program, we've split it in two tracks –
COMPANY BLOG
JOIN OUR MAILING LIST
Stay up to date on the latest news and announcements from LongeVC and our portfolio companies.
OFFICES
The future belongs to biotech founders
© All rights reserved, year 2023
© All rights reserved, year 2023
CONTACT
SOCIAL
Vesetas str.7, Riga LV-1013, Latvia
Via Calprino 18, CH - 6902, Lugano-Paradiso, Switzerland
